Navigation Links
Aethlon Medical Announces Approval and Initiation of Cancer Research Study to Target Tumor-Secreted Exosomes
Date:12/6/2011

ity to achieve the goals set out in the DARPA contract, future human studies of the Aethlon Hemopurifier® as an adjunct therapy to improve patient responsiveness to established cancer therapies, the Hemopurifier's® ability to capture tumor-secreted  exosomes and the impact it may have on disease conditions, the ability to successfully complete the Medanta HCV study and achieve positive results, the company's ability to raise capital when needed, the Company's ability to complete the development of its planned products, the Company's ability to manufacture its products either internally or through outside companies and provide its services, the impact of government regulations, patent protection on the Company's proprietary technology, product liability exposure, uncertainty of market acceptance, competition, technological change, and other risk factors. In such instances, actual results could differ materially as a result of a variety of factors, including the risks associated with the effect of changing economic conditions and other risk factors detailed in the Company's Securities and Exchange Commission filings.

James A. Joyce
Chairman and CEO
858.459.7800 x301
jj@aethlonmedical.com

Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com

Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com


'/>"/>
SOURCE Aethlon Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Aethlon Medical Releases Shareholder Letter
2. Aethlon Medical to Present at IN3 Medical Innovation Summit on October 27th
3. Aethlon Medical Announces Availability of its Exosome Detection Assay to the Research Community
4. Aethlon Medical Announces Hemopurifier® and HER2osome™ Cancer Therapy Presentation at Exosomes and Microvesicles 2011
5. "A Medical Device Strategy To Inhibit HER2+ Breast Cancer Progression" Released by Aethlon Medical, Inc.
6. Aethlon Medical Introduces HER2osome™, A Novel Therapeutic Device Strategy to Address Breast Cancer
7. Aethlon Medical Releases Shareholder Letter
8. Aethlon Medical to Discuss Recent Progress at the LHA Life Sciences & Medical Technologies Virtual Conference on June 16
9. Aethlon Medical to Present the Aethlon ADAPT™ System at C21 BioVentures™ Life Sciences Partnering Conference
10. Aethlon Medical Clarifies News Report
11. ABC News Reports on Aethlon Medical
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 By now, if you ... not living on this planet. The awareness campaign has brought ... has helped to raise over $88.5 Million (and counting) for ... and some companies are starting to as well. ... Orlando, Florida , who actually works with ALS sufferers ...
(Date:8/27/2014)... CHICAGO , Aug. 27, 2014  Hill-Rom Holdings, ... listen to a management presentation at the Morgan Stanley ... p.m. EDT. You are invited to listen ... http://ir.hill-rom.com/events.cfm or access it directly at ... be available one hour after conclusion of the live ...
(Date:8/27/2014)... North American lighting leader OSRAM SYLVANIA ... the new OSRAM ITOS ® PHASER ® 3000, ... microscopy, endoscopy and surgical head lamps that delivers the same ... lamp life. "We,re honored to be recognized by ... new technologies of the past year," said Andreas Osten ...
Breaking Medicine Technology:Acorn Stairlifts Gives a Lift to the ALS Ice Bucket Challenge 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 2OSRAM ITOS PHASER 3000 Laser and LED Light Module Recognized With Prestigious R&D 100 Award 3
(Date:8/27/2014)... in health care spending for commercially insured individuals is ... rather than increased use, according to a new study ... Policy & Clinical Practice, published in the August issue ... , There is increasing concern that consolidation in the ... by payers and, ultimately, consumers," said Carrie Colla, PhD, ...
(Date:8/27/2014)... 27, 2014 Scientists at The Scripps Research Institute ... signaling pathway can be associated with alcohol dependence. ... called neurofibromatosis type 1 (Nf1), which TSRI scientists found ... research shows Nf1 regulates gamma-aminobutyric acid (GABA), a neurotransmitter ... , "This novel and seminal study provides insights into ...
(Date:8/27/2014)... Dr. Winifred S. Hayes, President and CEO ... better health outcomes through the use of evidence, is ... to the executive team effective August 25, 2014. As ... responsible for providing innovation, leadership, and direction in the ... all markets. , “Maura is a highly respected ...
(Date:8/27/2014)... and dad, especially when your infant looks at you ... prattling, but by listening and responding, they let their ... forming complex sounds and using language more quickly. , ... of Iowa and Indiana University that found how parents ... way infants communicate and use vocalizations. , The findings ...
(Date:8/27/2014)... 2014 Will Holbrook, CP LP, has ... has over 15 years of experience in the prosthetics ... Georgia with a Bachelor of Science degree with a ... He received his graduate degree in prosthetics at Northwestern ... have Will join us at Fourroux,” says Keith Watson, ...
Breaking Medicine News(10 mins):Health News:Tracking spending among the commercially insured 2Health News:Scripps Research Institute scientists link alcohol-dependence gene to neurotransmitter 2Health News:Maura Connor Joins Hayes, Inc. as Vice President, Digital Publishing, Editor-in-Chief 2Health News:Parents, listen next time your baby babbles 2Health News:Parents, listen next time your baby babbles 3
... inadequate resources provided by the government to help the ... of treatment has left many stroke victims invalid. According ... with timely treatment and quality care. ,The ... victims with immediate brain scans, appropriate medication to dissolve ...
... a grant of $6 million for the Florida State ... for dyslexia in children.// The schedule involves understanding, ... grant will fund the creation of a National Institutes ... The center, which will be one of only four ...
... breast cancer who have been receiving the 30-year-old tamoxifen ... with the drug, Arimidex// under a new European licence ... AstraZeneca has stated that Arimidex, an aromatase inhibitor, will ... a partial course of tamoxifen.The license for this switch ...
... pass a law that would protect HIV/AIDS patient's rights to ... right// for a woman with the right to seek an ... ,India is supposedly the country with the highest number of ... this bill is being proposed to control this problem at ...
... the leading developmental disability. Statistics show that about 1.5 million ... a 10-17% increase in the disease ratio every year//. ... symptoms known to everyone the cause of the disease still ... brain developed by Dr. Stephen Grossberg, professor and chairman of ...
... taking part in an initiative to gauge if any ... who have suffered a stroke recently//. The MíTICO study ... Ictus. ,The study included patients from different Autonomous ... three months previously. By means of periodical controls, a ...
Cached Medicine News:Health News:Research Fund for FSU to Eradicate Dyslexia 2Health News:New Law On HIV/AIDS To Be Implemented At The Monsoon Session Of Parliament 2Health News:iSTART Brain Model Reveals the possible Cause of Autism 2Health News:iSTART Brain Model Reveals the possible Cause of Autism 3
Patent Pending lateral flow assay platform that contributes to increased sensitivty...
Iso-Electric Determination Kit; contains 1 bottle of 40 nm Naked Gold Iso-Electric Determination Kit to optimize gold conjugation of antibodies...
Gold Labeling kit for antibodies, the Coat-Block-Run Conjugation Kit pH 5-8; contains 1 bottle each of 20 nm and 40 nm Naked Gold...
Colloidal Gold Conjugated, Goat anti-rabbit IgG (H&L) - 50 OD...
Medicine Products: